Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers.
about
Immunotherapy as treatment for Alzheimer’s diseaseImmunotherapeutic approaches for Alzheimer's diseaseA safe, blood-brain barrier permeable triphenylmethane dye inhibits amyloid-β neurotoxicity by generating nontoxic aggregatesIntracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 miceNeuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates.Quantifying prefibrillar amyloids in vitro by using a "thioflavin-like" spectroscopic method.DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.Alzheimer's disease: is a vaccine possible?Effect of synthetic aβ peptide oligomers and fluorinated solvents on Kv1.3 channel properties and membrane conductance.Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathologyA retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies.Biphasic effects of insulin on islet amyloid polypeptide membrane disruption.Novel immunological approaches for the treatment of Alzheimer's disease.The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease.Autoreactive-Aβ antibodies promote APP β-secretase processing.A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Oxidative stress and mitochondria-mediated cell death mechanisms triggered by the familial Danish dementia ADan amyloidYeast expressed foldable quadrivalent Aβ15 elicited strong immune response against Aβ without Aβ-specific T cell response in wild C57BL/6 mice.Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trialDNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotypeAdvances on the understanding of the origins of synaptic pathology in AD.Soluble aggregates of the amyloid-beta peptide are trapped by serum albumin to enhance amyloid-beta activation of endothelial cells.Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques.Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.AD vaccines: conclusions and future directions.Glimpses of the molecular mechanisms of beta2-microglobulin fibril formation in vitro: aggregation on a complex energy landscapeRefinement of a DNA based Alzheimer's disease epitope vaccine in rabbits.Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Vaccination as a therapeutic approach to Alzheimer's disease.Murine models of Alzheimer's disease and their use in developing immunotherapies.Antibody-based therapy in Alzheimer's disease.Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.Designer protein disaggregases to counter neurodegenerative disease.Transthyretin binding to A-Beta peptide--impact on A-Beta fibrillogenesis and toxicity.Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice.Surface adsorption considerations when working with amyloid fibrils in multiwell plates and Eppendorf tubes
P2860
Q22241491-F1879B06-6765-4E88-979D-7EADFDFCFE86Q28081278-6E862387-CA68-49EA-8CDA-E219BC29BD03Q30423892-FF68086D-2063-42C7-BD6C-BCB7634823EDQ30486176-4A082D17-026B-4EE9-85FB-D4465A61BEE0Q30489052-7B2530AA-37EC-46C4-BD81-360AFB5FA3A6Q33332164-8AEEEBB0-071F-4478-9756-171070286B15Q33560798-977CC844-643B-4DDE-9948-589BBF2AE8D4Q33647141-472C98A3-4C02-48C7-AFE4-C613A80B081BQ33647708-9CBD9775-C25B-4971-9260-18B0952AAE02Q33725397-29F7AE40-3737-40BD-94E7-6732DF8D7F18Q33861011-75646CC8-B666-4377-BE5C-D0C698A9E138Q34259659-84CB0DC9-E382-43A6-8D37-FF3744E97A18Q34298878-4BE0D717-D72A-47F0-AA04-AFCB250F1344Q34518856-660B5AAA-2399-48EA-A1DF-5E89D93A17B6Q34536499-19AC4B0A-E58B-452F-81A9-26ACF911162FQ34562675-A076CF75-18C2-4908-9CD8-59F6C869B8F4Q35183183-D9F10B3E-D46D-41EB-B90F-BCE72E9D7749Q35753932-2251E12E-D040-4EC1-B66B-89B79A1F3723Q36240389-B56B4061-F4C7-4649-999D-9F90C698112AQ36396174-040832FF-23AF-452A-A6FA-0192FABC3585Q36552898-4F9E217E-A854-43C5-8672-3D16EE08ED52Q36631376-D819F0FA-53BA-4028-8509-F6D4730B61E4Q36790089-2F57C654-FE4D-4E2E-9596-33CDFE194B6EQ37086973-8F953F8F-98C4-411B-91BB-F7DAACCB3013Q37108156-06FE8B5D-27A3-4BD6-9B6E-C5807F715F71Q37196368-4E58D8B2-0385-4B6B-9C39-60B4B7A855D5Q37303082-A8A9C021-9F4D-46A5-A16A-A84E1FD594B7Q37438261-B716CDE9-577A-4721-920F-14A5F7F85878Q37438273-EDF4E624-1738-4CDF-A6BD-23A6F64A0B61Q37477467-BDA9F88A-0DA3-4874-BF72-C2DF95F6C812Q37505351-03CE3D29-C4CF-436C-B027-1ED89EC6767CQ37655247-0E1B25D3-8CBD-472F-94A7-44D8F7F8BB01Q37681432-631E72A1-FAE5-4E85-B9FF-F2946AEFFF0DQ37752915-5E10382B-8199-444C-991A-62B97728B946Q37831912-16AEFF95-03D6-4894-A590-16EF624FAC42Q37984574-AC9F73BA-E992-4234-B2CC-3FF3EBAD4A14Q39139060-920197DB-36F8-4B70-83BE-B7819902D6F3Q40009615-E9FF6D54-1983-4F68-ADAB-B5CF9C427688Q40041068-91079D45-E145-4B1F-BA9E-13E3AF4AD923Q42002681-D31027ED-095C-4AA7-9A41-F758BA81D76A
P2860
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Anti-A beta 1-11 antibody bind ...... not the most toxic oligomers.
@ast
Anti-A beta 1-11 antibody bind ...... not the most toxic oligomers.
@en
type
label
Anti-A beta 1-11 antibody bind ...... not the most toxic oligomers.
@ast
Anti-A beta 1-11 antibody bind ...... not the most toxic oligomers.
@en
prefLabel
Anti-A beta 1-11 antibody bind ...... not the most toxic oligomers.
@ast
Anti-A beta 1-11 antibody bind ...... not the most toxic oligomers.
@en
P2093
P2860
P356
P1476
Anti-A beta 1-11 antibody bind ...... t not the most toxic oligomers
@en
P2093
Charles G Glabe
David H Cribbs
Erene Mina
Grigor Mamikonyan
Irina Petrushina
Michael G Agadjanyan
Mihaela Necula
Mikayel Mkrtichyan
Nina Movsesyan
P2860
P304
22376-22386
P356
10.1074/JBC.M700088200
P407
P577
2007-06-01T00:00:00Z